Simultaneously and reliably quantify proteins, including post-translational modifications (PTMs), in a single-cell RNA sequencing (RNA-seq) assay using a streamlined protocol with approximately one hour of hands-on benchwork time
Danvers, MA, USA, October 1, 2024 – Cell Signaling Technology (CST), a life science discovery technology company and leading provider of antibodies, kits, and services, has announced the launch of InTraSeq™ Single Cell Analysis Reagents, a reliable, efficient and convenient way to simultaneously detect and study intracellular proteins and the transcriptome in a single-cell experiment, while guaranteeing a robust RNA signal. By combining InTraSeq technology with the 10x Genomics Single Cell Gene Expression Assay, researchers can rapidly categorize sub-populations of cells and unbiasedly resolve signaling pathways with single-cell resolution.
Analysis of isolated CD4+ and CD8+ cells using InTraSeq intracellular and signaling pathway antibodies to identify cellular states that would be difficult to study using RNA-seq alone. The InTraSeq assay provides unparalleled insights into cellular subpopulations, enabling a deeper understanding of disease mechanisms.
“For 25 years, CST has been the ‘go-to’ antibody company for studying cellular signaling and PTMs. InTraSeq technology brings this unparalleled expertise to single-cell analysis,” said Roby Polakiewicz, Chief Scientific Officer at CST. "The result is a groundbreaking new way to study intracellular signaling pathways at the single-cell level, representing a completely novel dataset that has been missing in current single-cell experiments. This enables researchers to comprehensively dissect the molecular mechanisms behind disease development using everything from surface markers to intracellular proteins, and PTMs to transcription factors—and finally, RNA sequencing—all in one assay.”
Features and Benefits of InTraSeq Technology
“Signaling transduction and gene transcription events, along with their relationship during T cell activation and cytokine signaling, have been a long-standing interest in the field of immunology,” said Dr. Vijay Kuchroo, PhD, DVM, Samuel L. Wasserstrom Professor of Neurology at Harvard Medical School, Senior Scientist at Brigham and Women’s Hospital, and a paid consultant for CST. “By measuring the abundance of proteins, along with their PTMs and the transcriptome at the exact moment for each individual cell, we can gain important insights into how signaling cascades interact with transcriptional regulation.”
InTraSeq Single Cell Analysis Reagents are available now as a ready-to-use cocktail of primary antibodies to 29 intracellular protein targets and two surface proteins, and as individual antibodies to 31 intracellular proteins and six surface proteins. They are reactive to humans and mice and have been validated by CST for use on the 10x Genomics Chromium instruments. Antibody cocktails relevant to signaling pathways related to immunology, cancer, and additional research areas are in development.
CST is known for antibody quality, and the company has been recognized by CiteAb for its commitment to validation standards, including being named the Post Translational Modification (PTM) Antibody Supplier of the Year in 2023 and the Antibody Supplier of the Decade in 2020.
To learn more and purchase InTraSeq Single Cell Analysis Reagents, visit: cellsignal.com/applications/intraseq-single-cell-overview
Cell Signaling Technology (CST) is a different kind of life science company—one founded, owned, and run by active research scientists, with the highest standards of product and service quality, technological innovation, and scientific rigor. Founded in 1999 and headquartered in Danvers, Massachusetts, USA, CST employs over 600 people worldwide. We consistently provide fellow scientists around the globe with best-in-class products and services to fuel their quests for discovery. CST is a company of caring people driven by a devotion to facilitating good science—a company committed to doing the right thing for our customers, our communities, and our planet. cellsignal.com
CST Media and Press
Rebecca J. Reppucci, MBA
Cell Signaling Technology, Inc.
Senior Director, Global MarComm & Technology
Phone: 978-880-3334
email: [email protected]
